Evaluatepharma believes that the pharmaceutical industry will see strong growth in 2015

Source: Ding Xiangyuan 2015-06-24 after four years of turbulence, the pharmaceutical industry seeks a stable direction By the end of this decade, the sales volume of the global life science industry is expected to increase by 5% This information comes from a new report of evaluatepharma analysis, which finds that emerging treatment categories and the approval of many breakthrough treatment drugs are rapidly promoting the sales of key drugs in the whole United States and Europe This, in turn, is driving an estimated 5% increase in global prescription drug sales over the next five years In 2014, the FDA approved 44 unprecedented drugs, eight of which are expected to sell more than $1 billion in sales five years after their launch EP analysts said that "sustained R & D productivity may finally be reaped." "After two years of sustained and rapid growth, concerns about a slowdown in the pharmaceutical industry can now subside," said Urquhart, editor of EP vantage However, she cautioned that drug pricing issues may hurt sales growth and the pharmaceutical industry needs to reconsider its pricing policy "For the pharmaceutical industry to sustain this impressive growth, they will have to make concessions in terms of global pricing and market access," she added "Similarly, pharmaceutical companies need to accept price cuts for their products or persuade payers that their treatment benefits outweigh the cost of the disease The report predicts that by 2020, the global sales of prescription drugs will reach about $1 trillion In 2014, U.S prescription drug sales soared by 8.9%, while growth in Europe also recovered, up 2.4% However, sales in Japan fell by 2.6% The autoinflammatory drug xiumeile (adamumumab) is still the best-selling product in 2014, with sales reaching US $13.9 billion In its first year on the market, Geely's hepatitis C pill sovaldi (sofosbuvir) became the world's second best-selling drug, with sales reaching $10 billion But it won't last, because this year, harvoni (ledipasvir / sofosbuvir), Gilead's new generation of therapeutic drugs, together with sovaldi, will become the world's best-selling therapeutic drugs EP also noted that Novartis will remain the No 1 pharmaceutical company by 2020, with total prescription drug sales of $53.3 billion last year Overall, the rebound means that 2015 will be a year of strong growth for the pharmaceutical industry, which is expected to return to sustained growth in the remaining 10 years For the pharmaceutical industry, the first half of this decade was a turbulent period Since 2011, a number of major blockbuster products began to lose their patents, Pfizer and AstraZeneca suffered a major impact, and Lilly's sales revenue decreased by billions of dollars Pfizer is actually the hardest hit The company lost patent protection in 2011-2012 for Lipitor, a statins drug with annual sales of US $13 billion, and its sales fell by US $10 billion in just two years However, EP said that the pharmaceutical industry is seeking to get rid of this dilemma In 2015, several drugs were launched, including new LDL anti PCSK9 drugs from Sanofi and Amgen, and mepolizumab, GlaxoSmithKline's severe asthma antibody The sales volume of these drugs is expected to be about 8 billion US dollars by 2020.